Sugi Predict

Sugi Predict / Compounds / SCHEMBL378510

SCHEMBL378510

SCHEMBL378510

COc1cc2nccc(Oc3ncc(NC(=O)CC(=O)Nc4cccc(C(F)(F)F)c4)cc3Cl)c2cc1OC

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 11/20 0.59
▸ BRAF P15056 5/20 0.56
▸ EGFR P00533 1/20 0.54
▸ FGFR4 P22455 1/20 0.54
▸ CSF1R P07333 2/20 0.53
▸ PDGFRB P09619 2/20 0.53
▸ FLT4 P35916 1/20 0.53
▸ FLT3 P36888 1/20 0.53
▸ PDGFRA P16234 6/20 0.53
▸ RET P07949 1/20 0.53
▸ KIT P10721 1/20 0.53
▸ DDR1 Q08345 1/20 0.53
▸ MAPK14 Q16539 1/20 0.53
▸ TNNI3K Q59H18 1/20 0.53
▸ RAF1 P04049 3/20 0.52
▸ AXL P30530 1/20 0.51
▸ MERTK Q12866 1/20 0.51
▸ MET P08581 2/20 0.50
▸ HDAC1 Q13547 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693652 1.00 KDR (0.59) KDRBRAFEGFRFGFR4CSF1R
SCHEMBL372681 0.90 PDGFRB (0.62) KDRBRAFCSF1RPDGFRBFLT4
SCHEMBL31324666 0.90 PDGFRB (0.62) KDRBRAFCSF1RPDGFRBFLT4
SCHEMBL29693548 0.90 PDGFRB (0.62) KDRBRAFCSF1RPDGFRBFLT4
SCHEMBL22566434 0.90 PDGFRA (0.56) KDRBRAFEGFRFGFR4CSF1R
SCHEMBL4400302 0.89 BRAF (0.69) KDRBRAFEGFRFGFR4CSF1R
SCHEMBL372713 0.89 KDR (0.63) KDRCSF1RPDGFRBFLT4FLT3
SCHEMBL371836 0.89 KDR (0.65) KDRCSF1RPDGFRBFLT4FLT3
SCHEMBL371958 0.88 PDGFRA (0.61) KDRCSF1RPDGFRBFLT4FLT3
SCHEMBL20525844 0.86 SMN1; SMN2 (0.49) KDRBRAFEGFRFGFR4MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 — — WO claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KDR 4/4885BRAF 10/4885EGFR 124/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET KDR 4/4885BRAF 10/4885EGFR 124/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 KDR 5/4885BRAF 13/4885EGFR 181/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KDR 4/4885BRAF 10/4885EGFR 124/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KDR 4/4885BRAF 10/4885EGFR 124/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET KDR 4/4885BRAF 10/4885EGFR 124/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 KDR 5/4885BRAF 13/4885EGFR 181/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 KDR 5/4885BRAF 13/4885EGFR 181/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET KDR 4/4885BRAF 10/4885EGFR 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.